| Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer T Golan, P Hammel, M Reni, E Van Cutsem, T Macarulla, MJ Hall, ... New England Journal of Medicine 381 (4), 317-327, 2019 | 2243 | 2019 |
| Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial K Shitara, M Özgüroğlu, YJ Bang, M Di Bartolomeo, M Mandalà, MH Ryu, ... The Lancet 392 (10142), 123-133, 2018 | 1271 | 2018 |
| Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up G Argilés, J Tabernero, R Labianca, D Hochhauser, R Salazar, T Iveson, ... Annals of Oncology 31 (10), 1291-1305, 2020 | 1093 | 2020 |
| Efficacy and safety of pembrolizumab for heavily pretreated patients with advanced, metastatic adenocarcinoma or squamous cell carcinoma of the esophagus: the phase 2 KEYNOTE … MA Shah, T Kojima, D Hochhauser, P Enzinger, J Raimbourg, ... JAMA oncology 5 (4), 546-550, 2019 | 483 | 2019 |
| EGFR nuclear translocation modulates DNA repair following cisplatin and ionizing radiation treatment G Liccardi, JA Hartley, D Hochhauser Cancer research 71 (3), 1103-1114, 2011 | 329 | 2011 |
| Mechanisms of multidrug resistance in cancer treatment AL Harris, D Hochhauser Acta Oncologica 31 (2), 205-213, 1992 | 273 | 1992 |
| Tracking the genomic evolution of esophageal adenocarcinoma through neoadjuvant chemotherapy N Murugaesu, GA Wilson, NJ Birkbak, TBK Watkins, N McGranahan, ... Cancer discovery 5 (8), 821-831, 2015 | 268 | 2015 |
| Chemotherapy with 5-fluorouracil, cisplatin and streptozocin for neuroendocrine tumours NC Turner, SJ Strauss, D Sarker, R Gillmore, A Kirkwood, A Hackshaw, ... British Journal of Cancer 102 (7), 1106-1112, 2010 | 237 | 2010 |
| SJG-136 (NSC 694501), a novel rationally designed DNA minor groove interstrand cross-linking agent with potent and broad spectrum antitumor activity: part 1: cellular … JA Hartley, VJ Spanswick, N Brooks, PH Clingen, PJ McHugh, ... Cancer research 64 (18), 6693-6699, 2004 | 229 | 2004 |
| Systemic treatment and liver transplantation for hepatocellular carcinoma: two ends of the therapeutic spectrum A Burroughs, D Hochhauser, T Meyer The lancet oncology 5 (7), 409-418, 2004 | 215 | 2004 |
| A phase I trial of antibody directed enzyme prodrug therapy (ADEPT) in patients with advanced colorectal carcinoma or other CEA producing tumours RJ Francis, SK Sharma, C Springer, AJ Green, LD Hope-Stone, L Sena, ... British journal of cancer 87 (6), 600-607, 2002 | 211 | 2002 |
| Cancer and its management JS Tobias, D Hochhauser John Wiley & Sons, 2009 | 209* | 2009 |
| The diagnosis and management of gastric cancer SG Thrumurthy, MA Chaudry, D Hochhauser, M Mughal Bmj 347, 2013 | 206 | 2013 |
| Communication with children and adolescents about the diagnosis of their own life-threatening condition A Stein, L Dalton, E Rapa, M Bluebond-Langner, L Hanington, KF Stein, ... The Lancet 393 (10176), 1150-1163, 2019 | 205 | 2019 |
| Determinants of anti-PD-1 response and resistance in clear cell renal cell carcinoma L Au, E Hatipoglu, MR de Massy, K Litchfield, G Beattie, A Rowan, ... Cancer cell 39 (11), 1497-1518. e11, 2021 | 197 | 2021 |
| Communication with children and adolescents about the diagnosis of a life-threatening condition in their parent L Dalton, E Rapa, S Ziebland, T Rochat, B Kelly, L Hanington, R Bland, ... The Lancet 393 (10176), 1164-1176, 2019 | 197 | 2019 |
| Ninety-six-hour paclitaxel infusion after progression during short taxane exposure: a phase II pharmacokinetic and pharmacodynamic study in metastatic breast cancer. AD Seidman, D Hochhauser, M Gollub, B Edelman, TJ Yao, CA Hudis, ... Journal of Clinical Oncology 14 (6), 1877-1884, 1996 | 172 | 1996 |
| Repair of DNA interstrand crosslinks as a mechanism of clinical resistance to melphalan in multiple myeloma VJ Spanswick, C Craddock, M Sekhar, P Mahendra, P Shankaranarayana, ... Blood, The Journal of the American Society of Hematology 100 (1), 224-229, 2002 | 168 | 2002 |
| A randomised phase II/III trial of 3-weekly cisplatin-based sequential transarterial chemoembolisation vs embolisation alone for hepatocellular carcinoma T Meyer, A Kirkwood, M Roughton, S Beare, E Tsochatzis, D Yu, N Davies, ... British journal of cancer 108 (6), 1252-1259, 2013 | 162 | 2013 |
| Overall survival results from the POLO trial: a phase III study of active maintenance olaparib versus placebo for germline BRCA-mutated metastatic pancreatic cancer HL Kindler, P Hammel, M Reni, E Van Cutsem, T Macarulla, MJ Hall, ... Journal of Clinical Oncology 40 (34), 3929-3939, 2022 | 156 | 2022 |
